![Spiros D. Garbis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Spiros D. Garbis
Sociétés | Poste | Début | Fin |
---|---|---|---|
Proteas Bioanalytics, Inc.
![]() Proteas Bioanalytics, Inc. Internet Software/ServicesTechnology Services Proteas Bioanalytics, Inc. is an innovative proteomics platform that advances molecular biology, biomarker development, and precision medicine. The private company is based in Torrance, CA and was founded by Spiros D. Garbis and Antigoni Manousopoulou. The company provides proteomics services and solutions to unmet needs in the field of neurodegenerative disorders, coronary artery disease, and cancer. Proteas Bioanalytics has collaborated with thought leaders and innovators in the medical field to develop novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma. Spiros D. Garbis has been the CEO since incorporation. | Directeur/Membre du Conseil | - | - |
Directeur Général | - | - | |
Directeur Technique/Scientifique/R&D | - | - | |
Fondateur | - | - | |
President | - | - |
Historique de carrière de Spiros D. Garbis
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Proteas Bioanalytics, Inc.
![]() Proteas Bioanalytics, Inc. Internet Software/ServicesTechnology Services Proteas Bioanalytics, Inc. is an innovative proteomics platform that advances molecular biology, biomarker development, and precision medicine. The private company is based in Torrance, CA and was founded by Spiros D. Garbis and Antigoni Manousopoulou. The company provides proteomics services and solutions to unmet needs in the field of neurodegenerative disorders, coronary artery disease, and cancer. Proteas Bioanalytics has collaborated with thought leaders and innovators in the medical field to develop novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma. Spiros D. Garbis has been the CEO since incorporation. | Technology Services |
- Bourse
- Insiders
- Spiros D. Garbis
- Expérience